These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 32055802)

  • 1. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
    Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
    J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
    Scott LJ
    Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series.
    Iannone LF; Fattori D; Geppetti P; De Cesaris F
    Neurol Sci; 2022 Jan; 43(1):697-703. PubMed ID: 34586542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galcanezumab for the prevention of cluster headache.
    Giani L; Proietti Cecchini A; Leone M
    Expert Opin Biol Ther; 2020 Oct; 20(10):1133-1142. PubMed ID: 32702245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galcanezumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Nov; 78(16):1769-1775. PubMed ID: 30378008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug profile: galcanezumab for prevention of cluster headache.
    Mudugal D; Monteith TS
    Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
    [No Abstract]   [Full Text] [Related]  

  • 12. [Galcanezumab for episodic and chronic cluster headache].
    Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
    Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medications Approved for Preventing Migraine Headaches.
    Spindler BL; Ryan M
    Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galcanezumab for the prevention of migraine.
    Frerichs LM; Friedman DI
    Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing Episodic Cluster Headaches: Focus on Galcanezumab.
    Pellesi L; De Icco R; Al-Karagholi MA; Ashina M
    J Pain Res; 2020; 13():1591-1599. PubMed ID: 32753938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.